Kolltan Pharmaceuticals, Inc.
300 George Street
New Haven, CT 06511
Crystal Smethurst/Investor Relations – email@example.com
Kolltan, a privately held clinical-stage company, is focused on advancing a new generation of therapeutics in oncology and other diseases by discovering and developing novel biologic agents designed to modulate the function of receptor tyrosine kinases (RTKs). Kolltan is led by an experienced team of executives and scientists with a deep understanding of RTKs, their ligands, and cellular signaling. Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is working in close collaboration with the laboratory of Kolltan co-founder, Dr. Joseph Schlessinger, as well as the Yale medical and scientific community to bring important medicines to cancer patients and other patients with serious diseases. The Company’s R&D pipeline is advancing rapidly, with the first clinical trial initiated in January 2014.
The current generation of cancer drugs, which act by interfering with the tyrosine kinase activity of oncogenic tyrosine kinases, has been remarkably successful in the treatment of a variety of cancers. Unfortunately, it is now clear that many patients responding to these drugs develop resistance in later dosing cycles, and ultimately fail therapy. Kolltan expects that the mechanism of action of its drugs will be unaffected by such resistance.
Kolltan’s strategy for its first disease target is to focus initially on the development of a therapeutic human mAb, due to its anticipated shorter path to regulatory approval, and later, on the possible discovery and development of synthetic small molecule therapeutics, to which Kolltan’s technology is equally applicable. Kolltan will assess additional targets through proof of principle experiments.
Kolltan’s offices and laboratories are located in New Haven, Connecticut in close proximity to the Schlessinger Laboratory at the Yale School of Medicine. Pursuant to an agreement with Yale University, Kolltan supports continuing RTK research in the Schlessinger Laboratory. Kolltan has not entered into any commercial partnership or collaboration agreements for the development or commercialization of any products but does expect to consider them as Kolltan’s portfolio matures.
CT Employees: 34
World Employees: 37